OncoCyte Corporation reported a significant increase in sales for Q4

From Nasdaq: 2025-03-24 18:00:00

OncoCyte Corporation reported a loss of -$33.51 million for the fourth quarter, compared to -$15.99 million last year. Revenue for the period increased by 373.2% to $1.486 million from $0.314 million. Earnings per share were -$1.93, down from -$1.96 last year. These figures reflect the financial performance of OncoCyte Corporation (OCX) in the recent quarter.



Read more at Nasdaq: OncoCyte Corporation (OCX) Q4 Sales Increase